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Abstract 
Background: Nucleic acid purification methods are of importance when performing microbiota studies and espe-
cially when analysing the intestinal microbiota as we here find a wide range of different microbes. Various considera-
tions must be taken to lyse the microbial cell wall of each microbe. In the present article, we compare several tissue 
lysis steps and commercial purification kits, to achieve a joint RNA and DNA purification protocol for the purpose of 
investigating the microbiota and the microbiota-host interactions in a single colonic mucosal tissue sample.
Results: A further optimised tissue homogenisation and lysis protocol comprising mechanical bead beating, lysis 
buffer replacement and enzymatic treatment, in combination with the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, 
Germany) resulted in efficient and simultaneous purification of microbial and human RNA and DNA from a single 
mucosal colonic tissue sample.
Conclusions: The present work provides a unique possibility to study RNA and DNA from the same mucosal biopsy 
sample, making a direct comparison between metabolically active microbes and total microbial DNA. The protocol 
also offers an opportunity to investigate other members of a microbiota such as viruses, fungi and micro-eukaryotes, 
and moreover the possibility to extract data on microbiota and host interactions from one single mucosal biopsy.
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Background
Crohn’s disease (CD) and ulcerative colitis, collectively 
known as inflammatory bowel diseases (IBD), are char-
acterized by chronic intestinal inflammation with huge 
impact on quality of life. The actual cause of IBD remains 
unsolved. It is likely, however, that the chronically recur-
ring episodes of inflammation in the human bowel are 
related to a complex interaction between various envi-
ronmental factors, a hereditary predisposition for these 
diseases and the gut microbiota [1, 2]. Host genetics play 
a key role, but genetic defects cannot explain the increas-
ing prevalence of IBD in recent years. One theory gaining 
support is that IBD results from, or is maintained by, a 
dysbiosis of the gut microbiota [3]. The human intesti-
nal tract harbors a diverse and complex microbial com-
munity playing a central role in human health [4]. The 
disruption of the delicate balance between the micro-
bial community and its host is thought to contribute to 
IBD pathogenesis. Unrevealing the inhabitants of the gut 
microbiota has been a goal for large research groups as 
the European MetaHIT (http://www.metahit.eu/) [5] and 
the US Human Microbiome Project (http://commonfund.
nih.gov/hmp/) [6]. Both projects have primarily focused 
on investigating the microbial diversity of fecal samples, 
as is also the focus of many other research groups [7]. In 
IBD, investigating fecal samples from affected persons is 
important and valuable, but as the disease includes the 
affection of colonic tissue, the mucosal microbiota is of 
high importance. Microbial communities that reside on 
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the surface of the intestinal mucosa encounter an envi-
ronment distinct from the luminal environment, and a 
recent study from Tang and coworkers [8] show that the 
mucosal microbiota may be a reservoir for species that 
contributes to disease activity in colitis. A recent study 
on new-onset CD also confirms the superiority of using 
mucosal biopsies as opposed to stool when searching for 
potential biomarkers, as presence or absence of bacterial 
taxa, for disease diagnosis [3].
Nucleic acid purification methods are of importance 
when performing microbiota studies, and especially when 
analysing the intestinal microbiota, as we here find a wide 
range of different microbes. Various considerations must 
be taken with regard to lysing the microbial cell wall of 
each microbe. The lysis step during nucleic acid purifi-
cation is thus an important step that could represent a 
large source of bias depending on the protocol used [9]. 
Studies have shown that the choice of DNA purifica-
tion methods, and more importantly the choice of pre-
homogenization procedures, has a large impact on the 
resulting microbiota composition and diversity [10, 11]. 
When assessing the success rate of a purification method, 
the method’s ability to purify ‘hard-to-lyse’ microbes, 
such as the Gram-positive Firmicutes, is often used for 
evaluation [12, 13]. Microbiota studies analysing both 
microbial RNA and DNA purified from mucosal biopsies 
have been performed, but in these studies RNA and DNA 
is purified from different mucosal biopsies [14, 15]. The 
aim of the present study is to purify both RNA and DNA 
for the purpose of investigating the metabolically active 
members of the microbiota, the total members of the 
microbiota and the microbiota-host interactions in a sin-
gle colonic mucosal sample. To achieve the aim we have 
optimised a joint RNA and DNA purification protocol 
of a commercial nucleic acid purification kit. The result-
ing optimised protocol has been assessed and evaluated 
against standard RNA and DNA purification methods.
Methods
Nucleic acid purification
Colonic mucosal biopsies, 2–3 mm in diameter, were col-
lected from two patients undergoing planned colectomy 
at Akershus University Hospital, and from three patients 
undergoing colonoscopy as part of the EU-project IBD-
Character (EU ref no 305676). Prior to the colectomy and 
colonoscopy the patients performed a bowel cleansing by 
Picoprep (Ferring Legemidler AS, Oslo, Norway) accord-
ing to manufacturer’s instructions. All biopsies were 
immediately placed in Allprotect Tissue Reagent (Qia-
gen, Hilden, Germany) and stored according to manu-
facturer’s instructions. For each of the different protocols 
tested, one to two biopsies from each patient were used 
due to a limited number of biopsies (Table 1).
Total RNA and DNA were purified from colonic 
mucosal tissue using the AllPrep DNA/RNA Mini Kit 
(Qiagen). Manufacturer’s instructions were followed 
with the exception of the lysis steps, where three tissue 
lysis protocols (Protocol 1, 2 and 3) were performed and 
evaluated (Fig.  1; Additional file  1). For RNA purifica-
tion, DNase treatment was included and performed on 
column as described in the AllPrep DNA/RNA Mini Kit 
protocol. RNA and DNA were eluted using 40 µl nucle-
ase free water (NFW) and stored at −80 and −20  °C, 
respectively.
The resulting RNA quantity and quality data from the 
tested protocols were compared to RNA quantity and 
quality data obtained using a standard RNA purification 
protocol combining Qiazol, phase separation and kit col-
umn based purification [16] (Table  1; Additional file  1). 
The resulting DNA quantity and quality data were com-
pared to DNA quantity and quality data from a combi-
nation of mechanical and enzymatic pre-treatments as 
recommended by Qiagen for lysis of Gram-positive bac-
teria, followed by purificaton with AllPrep DNA/RNA 
Mini Kit (kit 1), the QIAamp DNA Stool Mini Kit (kit 
2) and the DNeasy Blood & Tissue Kit (kit 3) (Table  1; 
Additional file 1). For all three purification kits the manu-
factures instructions were followed after pre-treatment. 
DNA was eluted using 40 µl NFW and stored at −20 °C.
The concentration of the RNA and DNA samples were 
assessed using NanoDrop ND-1000 spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA). For RNA 
quality the RNA integrity number (RIN) was tested using 
the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., 
Santa Clara, CA, USA) and the 2100 Expert Software. 
The assay and reagent kit used were Eukaryote Total RNA 
Nano Series II and the Agilent RNA 6000 Nano Kit. For 
DNA the quality was obtained using the ratio 260/280 for 
assessing the purity of the samples. The molecular size of 
the genomic DNA was measured in a 1 % agarose gel in 
1xTBE, 70 V, running time 2.5 h (Fig. 2).
cDNA synthesis
cDNA was synthesised from 200  ng RNA using Accu-
Script High Fidelity 1st Strand cDNA Synthesis Kit (Agi-
lent Technologies Inc.) according to the manufacturer’s 
instructions. Both gene specific primer (926R [17]) and 
random hexamers were tested, with technical replicates, 
on RNA purified using protocol 2 and tissue biopsies 
from three patients. Two RNA samples were run in the 
absence of reverse transcriptase to assess the degree 
of contaminating genomic DNA. To verify synthesis 
of microbial and human cDNA and to assess possible 
contaminating genomic DNA real-time PCR was per-
formed using ABI Prism 7900HT Real Time PCR System 
(Applied Biosystems, Thermo Fisher Scientific, Waltham, 
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MA, USA) and the software system SDS 2.4 (Applied 
Biosystems). The primers used for microbial 16S cDNA 
amplification were 357F and 926R [17], and for human 
cDNA amplification ACTB-F: 5′-GGT GTT TGT CTC 
TCT GAC TAG-3′, and ACTB-R: 5′-TGT CAC ACG 
AGC CAG TAT TAG-3′ [18]. The PCR amplifications 
were performed in triplicates using a 20 µl final reaction 
mixture containing 10 µl Power SYBR Green PCR Master 
mix (Applied Biosystems), 4 µl primer mix (5 µM), 4 µl 
NFW and 2 µl template. Default cycling conditions were 
used (Applied Biosystems)(Additional file 2).
Cloning and sequencing of 16S rRNA and 16S cDNA
The 16S rRNA genes and 16S cDNA were amplified using 
primers 357F and 926R [17], HotMaster Taq DNA poly-
merase (5 PRIME GmbH, Hilden, Germany) and the 
following cycling conditions: Initial denaturation 94  °C 
(2 min), 94 °C (30 s) 58 °C (30 s) 65 °C (45 s), 30 cycl., 65 °C 
(7 min). Cloning of the amplified products were performed 
using TOPO® TA cloning (Life Technologies, Thermo 
Fisher Scientific, Waltham, MA, USA) according to manu-
facturer’s instructions. Positive clones were subjected to 
PCR amplification using M13 primers from the cloning kit 
and cycling conditions according to manufacturer’s instruc-
tions. The PCR products were sequenced using Big Dye 
v/1.1, primers 357F and 926R [17] and ABI3130xl (Applied 
Biosystems) according to manufacturer’s instructions.
The 16S rRNA gene cloning and sequencing was per-
formed using DNA purified from biopsies with protocol 
1, 2 and 3 and DNA purified by the three different DNA 
extraction kits (kit 1–3) after enzymatic and mechanical 
pre-treatment (Table  1). For protocol 2 and 3 technical 
replicates were used. The 16S cDNA cloning and sequenc-
ing was performed on cDNA being synthesised from RNA 
purified from one biopsy using protocol 2. Two different 
cDNA synthesis reactions, containing either gene specific 
primer or random hexamers as described above, were 
used in the cloning and sequencing reactions (Table 1).
Taxonomic assignment and data analyses
The sequences were analysed using Sequencher v/5.2 
(Gene Codes Corporation, Ann Arbor, MI, USA). Chimera 
checking was performed using USEARCH 6.0. [19]. The 
sequences were taxonomically classified using Classifier, 
a naïve Bayesian classifier (http://rdp.cme.msu.edu/clas-
sifier/classifier.jsp) [20], and the 16S rRNA training set 14 
Table 1 Purified DNA and RNA quantity and quality data and subsequent analysis
a Three separate comparisons of purification protocols were performed due to limited number of biopsies
b X = Sample being subjected to cDNA synthesis, T = Technical replicates
c X = Sample being subjected to cloning and sequencing, T = Technical replicates













1 Patient 1 Protocol 1 540 1.89 48.34 N/A X
Patient 1 Protocol 2 429 1.89 97.67 8.3 X (T)
Patient 1 DNA kit1 258 1.90 X
Patient 1 DNA kit2 353 1.88 X
Patient 1 DNA kit3 219 1.88 X
Patient 2 Protocol 1 366 1.88 38.95 N/A
Patient 2 Protocol 2 200 1.92 85.12 8.5 X (T)
Patient 2 DNA kit1 117 1.91
Patient 2 DNA kit2 389 1.87
Patient 2 DNA kit3 551 1.86




Patient 3 Protocol 2 109.82 8.7 X (T)




Patient 3 Protocol 2 102.2 8.9 X (T) X
3 Patient 4 Protocol 2 375 1.89 116.96 8.1 X (T)
Patient 5 Protocol 2 521 1.88 56.26 7.3 X (T)
Patient 4 Protocol 3 274 1.92 170.42 7 X (T)
Patient 5 Protocol 3 353 1.90 102.27 7.3 X (T)
Page 4 of 9Moen et al. BMC Res Notes  (2016) 9:328 
(accession date 7 Apr 2016). Comparison analysis of DNA 
purified using different purification protocols and com-
parison analysis of cDNA synthesized using different oli-
gonucleotides, were performed using the Library Compare 
Tool, with default settings, found at http://rdp.cme.msu.
edu/comparison (accession date 7 Apr 2016) and described 
in the paper of Wang et al. [20]. Shannon diversity indexes 
were calculated to measure the richness and eveness for 
the libraries using the Shannon & Chao index tool from the 
RDP Pipeline (https://pyro.cme.msu.edu/index.jsp) and a 
3 % distance [20] (accession date 7 Apr 2016). Rarefaction 
curves were calculated using the Rarefraction tool (https://
pyro.cme.msu.edu/rarefaction/form.spr) with default set-
tings (accession date 4 May 2016).
Results and discussion
We have developed further a commercial nucleic acid 
protocol for efficient and simultaneous purification 
of microbial and human RNA and DNA from a single 
mucosal colonic tissue sample. The protocol is based 
upon widely used methods and allows for the combined 
study of metabolically active, latent and dead bacteria in 
and on the colonic mucosa. The isolated RNA and DNA 
will be the total RNA and DNA of the sample, thereby 
also offering a unique opportunity to investigate microbi-
ota-host interactions in a single mucosal biopsy as well as 
micro-eukaryotes and viruses.
Nucleic acid purification: protocol 1 and 2 and standard 
purification methods
Isolating RNA and DNA from a wide range of bacteria 
from one tissue sample can be challenging as some bac-
terial orders and species have ‘hard-to-lyse’ cell walls, 
making rough pre-treatment necessary. Other bacteria 
will lyse rapidly and exposure of their free nucleic acids 
to rough treatment can result in RNA and DNA fragmen-
tation. We started by comparing two protocols, proto-
col 1 and 2 (Table  1; Fig.  1; Additional file  1) on tissue 
biopsies from two patients. In protocol 1, the tissues were 
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Fig. 1 Protocol flowchart. Flowchart of the experimental set-up of protocol 1, 2 and 3
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RLT Plus before proceeding with RNA and DNA puri-
fication by AllPrep DNA/RNA Mini Kit (Qiagen) using 
kit instructions. In protocol 2 the lysates were replaced 
with fresh buffer RLT Plus between each round of bead 
beating and finally the lysates were combined before 
proceeding with RNA and DNA purification following 
the kit protocol. In the latter procedure we hypothesised 
that the free nucleic acids released to the lysate after each 
bead beating would be more protected as it was not being 
exposed to additional bead beating.
The quantity and quality of DNA was comparable 
between the protocols 1 and 2 as assessed by NanoDrop 
(Table 1). Agarose gel electrophoreses indicated that both 
protocols gave high molecular genomic DNA (Fig.  2). 
The DNA from protocol 1 showed signs of fragmenta-
tion indicating that the DNA was affected to a certain 
extent by the high degree of rough pre-treatment. For 
RNA the quantity was comparable between the protocols 
1 and 2 as assessed by NanoDrop (Table 1). For the qual-
ity assessments no RIN could be calculated for neither of 
two RNA samples obtained from protocol 1 due to the 
reduction in peak height for the 28S fragment (Table  1; 
Fig. 3). The peak height reduction in 28S could indicate a 
fragmentation of the RNA when exposing the free nucleic 
acids to repeated bead beating. Another reason could be 
biological difference between two tissue biopsies col-
lected from one person, resulting in RNA from one of the 
biopsies having good quality and from the second a less 
optimal quality. The observation of the same pattern in 
two individuals favours the treatment during RNA puri-
fication being responsible for the peak height reduction. 
The number of samples is limited and a certain conclu-
sion cannot be drawn. The peak height reduction of RNA 
28S after being exerted to protocol 1 however, indicate 
that the RNA is of less good quality compared to the 
RNA purified using protocol 2. The importance of high 
RIN values is discussed in literature and varies according 
to downstream analysis [21, 22]. A low RIN value would 
possibly not influence a 16S cDNA sequencing analysis, 
but a high quality RNA sample is preferable to keep the 
RNA suitable for most downstream analyses.
For purification of microbial DNA, enzymatic lysis is 
recommended for effective disruption of bacterial cell 
walls [11]. The quantity and quality of DNA purified using 
bead beating only (protocol 1 and 2) was comparable to 
DNA purified using a combination of bead beating and 
enzymatic lysis for all three DNA purification kits tested 
(kit 1–3) (Table 1). However, each method favoured dif-
ferent bacterial phyla. Bead beating and enzymatic lysis 
in combination with the AllPrep DNA/RNA Mini Kit 
showed to be superior in breaking the ‘hard-to-lyse’ cell 
walls of the Firmicutes phylum (Fig. 4).
RNA purification using a combination of Qiazol, or 
other chaotropic solutions, phase separation and puri-
fication kit columns, is a standard method for different 
types of sample material [16]. The quality of RNA using 
the standard RNA purification method had comparable 
values to RNA isolated using protocol 2, supporting pro-
tection of RNA in protocol 2 (Table 1; Additional file 2). 
Due to shortage of biopsies from patient 1 and 2 this 
comparison was performed on patient 3 using four biop-
sies, two biopsies per method tested (Table 1).
Nucleic acid purification: protocol 3
The microbial and human RNA is prone to be degraded 
by RNases present in the human tissue. In the tis-
sue lysis protocol of the AllPrep DNA/RNA Mini Kit, 
RNases and other proteins are efficiently denatured by 
β-mercaptoethanol added in the buffer RLT Plus. The 
finding of bead beating and enzymatic lysis in combina-
tion with the AllPrep DNA/RNA Mini Kit being superior 
in breaking the ‘hard-to-lyse’ cell walls of the Firmicutes 
phylum (Fig. 4) resulted in development of protocol 3 in 
an attempt to use enzymatic lysis and bead beating and 
still preserve microbial and human RNA. Protocol 3 is a 
combination of protocol 2 and a modified version of the 
enzymatic lysis procedure for stool samples published by 
Franzosa and colleagues [23]. The enzymatic lysis step 
was performed after the first two rounds of mechanical 
tissue lysis and buffer replacement when RNases present 
Fig. 2 DNA quality. Gel electrophoresis of genomic DNA (1 % 
agarose gel in 1xTBE, 70 V, running time 2.5 h) 1 and 5 1 kB Plus DNA 
ladder (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA); 2 
Protocol 1 (100 ng); 3 Protocol 2 (100 ng); 4 Lambda DNA-48 kB (New 
England Biolabs, Ipswich, MA, USA)
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in the human tissue would have been denatured. The 
β-mercaptoethanol in buffer RLT Plus will denature lysis 
enzymes and the remains of the buffer RLT Plus had to 
be washed out of the beads, tissue debris and unlysed 
bacterial cells. This was performed as described in proto-
col 3 (Additional file 1). The enzymatic lysis step did not 
affect the RNA quality, suggesting that tissue RNases had 
been degraded in the first part of the tissue lysis protocol 
and that the proteinase K added together with the lysis 
enzymes protected the RNA from further degradation 
(Table 1).
The comparison of microbial DNA and RNA purified 
from nine biopsies from four patients by cloning and 
sequencing resulted in a total library of 2297 sequences. 
A total of 59 putative chimeric sequences, identified 
by USEARCH, were removed from the data set (Addi-
tional file 2). To estimate the relative diversity of DNA 
libraries achieved by protocol 2 and 3 for each patient, 
Fig. 3 RNA quality values for purification using protocol 1 and 2. Bioanalyser electropherograms of RNA isolated using protocol 1 and 2. Fragment 
peaks are eukaryotic 18S and 28S
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we calculated the Shannon index. The microbiota diver-
sity was not found to be significantly different between 
purification protocol 2 (mean 3.87 ± 0.03) and protocol 
3 (mean 4.04 ± 0.18). As demonstrated by the rarefac-
tion curves, the number of sequences analysed from 
each library was adequat for comparisons at order level 
(Additional file  2).The Library Compare tool was used 
to discover which bacterial groups were differentially 
abundant between the the libraries of protocol 2 and 3. 
The analyses indicated that for patient 4 a robust statis-
tically significant difference between the the two librar-
ies existed (p  =  1.59  ×  10−6), whereas no significant 
difference was found for patient 5 (p  =  3.17  ×  10−1) 
(Fig.  5). Interestingly, the importance of enzymatic 
treatment (protocol 3) seems to decrease with increas-
ing abundance of Firmicutes. Similar results have also 
been observed when comparing DNA libraries from 
protocol 2 with DNA purified by the AllPrep standard 
protocol in combination with enzymatic pre-treatment 
(data not shown).
The DNA purified by protocol 3 showed consistency 
with the standard DNA purification methods using enzy-
matic lysis as a first step in the protocol (and hence no co-
purification of RNA) followed by bead beating, regarding 
the relative amount of the bacterial phylum Firmicutes 
(Fig. 5). The benefit from protocol 3 is clear from patient 
4 where the Firmicutes content is changed from 35 to 
50 %. The benefit is less clear from patient 5, nevertheless 
no loss of Firmicutes is observed. We therefore argue that 
as a total, protocol 3 will insure a capture of as much of 
the ‘hard-to-lyse’ bacteria as possible.
cDNA synthesis
16S cDNA amplicon sequencing is performed to investi-
gate the metabolically active members of the microbiota. 
In a human tissue sample most RNAs will be of human ori-
gin and the use of random hexamers in the cDNA synthe-
sis could result in synthesis of human RNA at the expense 
of microbial RNA. However, the use of 16S gene specific 
primer will lead to a selective synthesis of cDNA and the 
selection depends on the primer used [24–26]. In the present 
study RNA purified from patients 1, 2 and 3 using protocol 
2 were subjected to cDNA synthesis. Real time PCR showed 
lack of contaminating genomic DNA in the RNA samples. 
Both gene specific primer and random hexamers were used 
in the cDNA synthesis to investigate possible differences in 
the efficiency of the cDNA synthesis reaction and to inves-
tigate the bacterial taxonomic distribution obtained from 
the two reactions. The cDNA synthesized with gene specific 
primer was found to be more efficient than using random 
primers as illustrated in the real-time PCR results (Addi-
tional file 2). This shows that the use of gene specific primer 
will result in selective cDNA synthesis and that human RNA 
is synthesized to cDNA at the expense of microbial RNA 
using random primers. We found that both primer types 
revealed approximately the same bacterial taxonomic dis-
tribution after cloning and sequencing (Fig.  6). Due to the 
limited number of sequences in this analysis a recommenda-
tion is to keep in mind the selective process of a gene specific 
primer in the cDNA synthesis and perform a test run or pilot 
study before running an experiment.
Our study has additional limitations. The number of 
biopsies from each patient in the study is limited. This 
hindered the testing of all protocols on the same patient 
material. In addition this limitation resulted in lack of 
biological replicates in the study.
Fig. 4 Comparison on taxonomic level of DNA purification using 
protocol 1 and commonly used DNA purification methods. The 16S 
sequence comparison bar charts are made using Classifier (http://
rdp.cme.msu.edu/classifier/classifier.jsp). The significant differences 
of Firmicutes between paired libraries were calculated by the Library 
Compare Tool using a confidence threshold of 80 % (http://rdp.cme.
msu.edu/comparison). Protocol 1: Mechanical pre-treatment only, 
followed by purification with AllPrep DNA/RNA Mini Kit as described 
in Additional file 1; DNA kit 1, 2 and 3: A combination of mechanical 
and enzymatic pre-treatments as recommended by Qiagen for lysis 
of Gram-positive bacteria, followed by purificaton with AllPrep DNA/
RNA Mini Kit (kit 1), QIAamp DNA Stool Mini Kit (kit 2) and DNeasy 
Blood & Tissue Kit (kit 3) as described in Additional file 1. n number of 
clones sequenced
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Conclusions
The results of the present work give a unique possibility 
to study RNA and DNA from the same mucosal biopsy 
sample, making a direct comparison between meta-
bolically active microbes and total microbial DNA. The 
protocol also offers an opportunity to investigate other 
members of a microbiota such as viruses, fungi and 
micro-eukaryotes in addition to the possibility to extract 
data on microbiota and host interactions from one single 
mucosal biopsy.
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